Genzyme Licenses Dx Rights to Moffitt Proteins for Lung Cancer Test | GenomeWeb
NEW YORK (GenomeWeb News) – Genzyme has licensed the diagnostic testing rights to two proteins from the Moffitt Cancer Center that it plans to develop into tests that could help predict patients’ response to non-small cell lung cancer treatments, the company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

In Nature this week: genetic history of HIV in the US, and more.